US pain trial

Gotta be happy with this happy days

Zelira US Observational Clinical Pain Trial Receives IRB Approval• Institutional Review Board (IRB) approval received, allowing Zelira’s pain observational trial in USA to proceed • Study will be a head-to-head study against a major Big Pharmaceutical company’s multi-billion-dollar revenue drug, using Zelira’s proprietary, patent protected product• Preliminary results expected in 1H of 2022• Zelira continues to lead the world in creating and validating proprietary products such as Zenivol® with a focus on taking these drugs through regulatory registration. Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabinoid-based medicines, is pleased to announce that it has obtained IRB approval for its 12 week Observational Clinical Study to evaluate the efficacy, safety and tolerability of its proprietary, patent protected product against a multi-billion dollar Big Pharmaceutical company drug.Zelira has successfully navigated a unique regulatory path for this trial and looks forward to the results of the study, which is anticipated to be available in the first half of 2022. Zelira continues to lead the world in creating and validating proprietary products such as Zenivol®, with a focus on taking these drugs through regulatory registration. Zelira Therapeutics Chairman, Osagie Imasogie commented: “We are very pleased with receiving our IRB approval. We are even more pleased that we can conduct this innovative trial that we hope will provide additional safe and effective options for physicians and patients in the treatment of pain caused by neuropathy.”This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.